Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world registry study of cenobamate for focal epilepsy
ChiCTR2600131435Phase 4Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cenobamate in Focal Onset Epilepsy, sponsored by Beijing Tiantan Hospital. Primary endpoints: Proportion of patients with at least 50% reduction in frequency of all seizures and Responder rate at follow-up. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
cenobamate
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on ChiCTR2600131435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131435.